To commercialize our products in both foreign and domestic markets, we have established and continue to actively pursue strategic partnerships. Our stringent criteria ensure our strategic partners have the market knowledge and sales force capacity to sell our products in the specific markets they will address.
Watson Pharmaceuticals owns rights to CRINONE® 8% and 4% progesterone vaginal gels in the United States.
Merck Serono S.A. is our global partner for CRINONE® (progesterone gel) for all territories outside the U.S. market.
Columbia sold U.S. rights to STRIANT to Actient Pharmaceuticals LLC in April 2011. The Urology Company markets STRIANT in the United Kingdom and certain other European countries. Invaron Pharmaceuticals holds license and marketing rights to STRIANT in Canada. Other regions are available for license.
